Tiziana Life Sciences (NASDAQ:TLSA) Stock Price Down 0.9% - Should You Sell?

Key Points

• Tiziana Life Sciences shares fell 0.9% to $1.08, with trading volume down 77% from the average session. The stock remains below its 50-day and 200-day moving averages of $1.10 and $1.25, respectively.
• Analyst sentiment is cautious: one analyst rates the stock “Hold” and another “Sell,” producing a consensus rating of “Reduce.”
• Insiders have shown buying interest, with CEO Ivor Elrifi purchasing 237,616 shares and insiders acquiring nearly 1 million shares over the past 90 days; insiders own 39.82% of the company.

Tiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report)'s share price was down 0.9% on Thursday . The stock traded as low as $1.05 and last traded at $1.08. Approximately 272,314 shares were traded during trading, a decline of 77% from the average session volume of 1,175,750 shares. The stock had previously closed at $1.09.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on TLSA shares. Weiss Ratings lowered Tiziana Life Sciences from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday, May 29th. Zacks Research upgraded shares of Tiziana Life Sciences to a "hold" rating in a research note on Tuesday, July 14th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of "Reduce".

Tiziana Life Sciences Stock Down 0.9%

The business has a 50 day moving average price of $1.10 and a 200 day moving average price of $1.25.

Insider Activity at Tiziana Life Sciences

In other news, CEO Ivor Elrifi acquired 237,616 shares of the company's stock in a transaction dated Wednesday, August 5th. The shares were acquired at an average price of $1.00 per share, with a total value of $237,616.00. Following the purchase, the chief executive officer directly owned 4,793,684 shares of the company's stock, valued at $4,793,684. This trade represents a 5.22% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders have purchased 988,423 shares of company stock worth $985,909. 39.82% of the stock is owned by company insiders.

Hedge Funds Weigh In On Tiziana Life Sciences

Several institutional investors and hedge funds have recently bought and sold shares of the company. Rachor Investment Advisory Services LLC acquired a new stake in shares of Tiziana Life Sciences during the 4th quarter worth approximately $25,000. Cubist Systematic Strategies LLC acquired a new stake in Tiziana Life Sciences during the first quarter worth $25,000. Marshall Wace LLP purchased a new stake in Tiziana Life Sciences in the second quarter valued at $39,000. HRT Financial LP purchased a new position in shares of Tiziana Life Sciences during the 4th quarter worth $36,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in Tiziana Life Sciences in the fourth quarter valued at approximately $59,000.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences plc NASDAQ: TLSA is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company's lead small‐molecule program, milciclib, is an oral cyclin‐dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source